公开(公告)号：US5591828A

公开(公告)日：1997-01-07

申请号：US317612

申请日：1994-09-29

申请人： Klaus Bosslet ,  Peter Hermentin ,  Gerhard Seemann ,  Ludwig Kuhlmann ,  Axel Steinstr asser

发明人： Klaus Bosslet ,  Peter Hermentin ,  Gerhard Seemann ,  Ludwig Kuhlmann ,  Axel Steinstr asser

IPC分类号： A61K31/00 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  C07K1/22 ,  C07K14/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  C07K16/28

CPC分类号： C07K16/468 ,  C07K16/3007 ,  A61K38/00

摘要： The invention relates to bispecific and oligospecific, mono- and oligovalent receptors which are prepared by gene manipulation by fusion of DNA coding for F(ab) fragments of antibodies of two or more different specificities by means of suitable linkers. In this connection, one specificity is preferably directed either against an epitope, which is located on the cell membrane or in the interstitium, of a tumor-associated antigen (TAA) or against an epitope in the tumor endothelium (TE), while the other specificities relate to high-molecular or low-molecular weight ligands and react, for example, with the Komplexons ethylenediaminetetraacetate and diethylenetriaminepentaacetate in Y90 complexed form (EDTA-Y90 and DTPA-Y90 respectively). In a particularly preferred embodiment, the binding with the Komplexons takes place on the Komplexon receptor arm via fos-jun interaction (or else avidin-biotin interaction). Other preferred specificities have catalytic properties.

摘要翻译： 本发明涉及双特异性和寡特异性，单低分子和低聚受体，其通过用适当的接头对通过融合编码两种或多种不同特异性的抗体的F（ab）片段的DNA进行融合来制备。 在这方面，一个特异性优选地针对肿瘤相关抗原（TAA）或肿瘤内皮（TE）中的表位位于细胞膜或间质的表位，而另一个 特异性涉及高分子量或低分子量配体，例如与Y90络合形式的乙二胺四乙酸钴和二亚乙基三胺五乙酸酯反应（分别为EDTA-Y90和DTPA-Y90）。 在特别优选的实施方案中，与Komplexons的结合通过fos-jun相互作用（或者亲和素 - 生物素相互作用）发生在Komplexon受体臂上。 其它优选的特性具有催化性质。